Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Peddi, PF; Fasching, PA; Liu, D; Quinaux, E; Robert, NJ; Valero, V; Crown, J; Falkson, C; Brufsky, A; Cunningham, JM; Weinshilboum, RM; Pienkowski, T; Eiermann, W; Martin, M; Bee, V; Wang, XY; Wang, LW; Yang, ER; Slamon, DJ; Hurvitz, SA.

Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

CLINICAL CANCER RESEARCH. 2022; 28(9): 1854-1862 Nº de citas: 8 [doi:10.1158/1078-0432.CCR-21-1762]

Campone, M; De Laurentiis, M; Zamagni, C; Kudryavcev, I; Agterof, M; Brown-Glaberman, U; Palacova, M; Chatterjee, S; Menon-Singh, L; Wu, JW; Martin, M.

Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

BREAST CANCER RESEARCH AND TREATMENT. 2022; 193(1): 95-103 Nº de citas: 7 [doi:10.1007/s10549-022-06543-1]

Agnelli, G; Munoz, A; Franco, L; Mahe, I; Brenner, B; Connors, JM; Gussoni, G; Hamulyak, EN; Lambert, C; Suero, MR; Bauersachs, R; Torbicki, A; Becattini, C.

Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

THROMBOSIS AND HAEMOSTASIS. 2022; 122(05): 796-807 Nº de citas: 37 [doi:10.1055/s-0041-1735194]

Cottu, P; Ring, A; Abdel-Razeq, H; Marchetti, P; Cardoso, F; Bofill, JS; Martin, M; Menon-Singh, L; Wu, JW; De Laurentiis, M.

Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial

BREAST. 2022; 62: 75-83 Nº de citas: 8 [doi:10.1016/j.breast.2022.01.016]

Duca, M; Lim, DWT; Subbiah, V; Takahashi, S; Sarantopoulos, J; Varga, A; D'Alessio, JA; Abrams, T; Sheng, Q; Tan, EY; Rosa, MS; Gonzalez-Maffe, J; Sand-Dejmek, J; Fabre, C; Martin, M.

A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

MOLECULAR CANCER THERAPEUTICS. 2022; 21(4): 625-634 Nº de citas: 5 [doi:10.1158/1535-7163.MCT-21-0652]

Verso, M; Agnelli, G; Munoz, A; Connors, JM; Sanchez, O; Huisman, M; Brenner, B; Gussoni, G; Cohen, AT; Becattini, C.

Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study

EUROPEAN JOURNAL OF CANCER. 2022; 165: 136-145 Nº de citas: 10 [doi:10.1016/j.ejca.2022.01.023]

Blum, JL; Laird, AD; Litton, JK; Rugo, HS; Ettl, J; Hurvitz, SA; Martin, M; Roche, HH; Lee, KH; Goodwin, A; Chen, Y; Lanzalone, S; Chelliserry, J; Czibere, A; Hopkins, JF; Albacker, LA; Mina, LA.

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

CLINICAL CANCER RESEARCH. 2022; 28(7): 1383-1390 Nº de citas: 12 [doi:10.1158/1078-0432.CCR-21-2080]

Valderrama, BP; Gonzalez-del-Alba, A; Morales-Barrera, R; Fernandez, IP; Vazquez, S; Diaz, CC; Domenech, M; Calvo, OF; Lista, AGD; Arija, JAA.

SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 613-624 Nº de citas: 9 [doi:10.1007/s12094-022-02815-w]

Majem, M; de las Penas, R; Virizuela, JA; Cabezon-Gutierrez, L; Cruz, P; Lopez-Castro, R; Mendez, M; Mondejar, R; Munoz, MD; Escobar, Y.

SEOM clinical guideline emesis (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 712-723 Nº de citas: 6 [doi:10.1007/s12094-022-02802-1]

Felip, E; Moreno, V; Morgensztern, D; Curigliano, G; Rutkowski, P; Trigo, JM; Calvo, A; Kowalski, D; Cortinovis, D; Plummer, R; Maio, M; Ascierto, PA; Vladimirov, VI; Cervantes, A; Zudaire, E; Hazra, A; T'jollyn, H; Bandyopadhyay, N; Greger, JG; Attiyeh, E; Xie, H; Calvo, E.

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2022; 89(4): 499-514 Nº de citas: 7 [doi:10.1007/s00280-022-04414-6]

Echavarria, I; Galindo, JRC; Corral, J; Tain, MPD; Carrasco, FH; Gonzalez-Cruz, VI; Mielgo-Rubio, X; Quintanar, T; Corredor, CR; Segura, PP.

SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(4): 724-732 Nº de citas: 9 [doi:10.1007/s12094-022-02800-3]

Elez, E; Gomez-Espana, MA; Gravalos, C; Garcia-Alfonso, P; Ortiz-Morales, MJ; Losa, F; Diaz, IA; Grana, B; Toledano-Fonseca, M; Valladares-Ayerbes, M; Polo, E; Salgado, M; De Castro, EM; Safont, MJ; Salud, A; Ruiz-Casado, A; Tabernero, J; Riesco, MD; Rodriguez-Ariza, A; Aranda, E.

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

BRITISH JOURNAL OF CANCER. 2022; 126(6): 874-880 Nº de citas: 5 [doi:10.1038/s41416-021-01638-w]

Garcia-Saenz, JA; Martinez-Janez, N; Cubedo, R; Jerez, Y; Lahuerta, A; Gonzalez-Santiago, S; Ferrer, N; Ramos, M; Alonso-Romero, JL; Anton, A; Carrasco, E; Chen, JJ; Neuwirth, R; Galinsky, K; Vincent, S; Leonard, EJ; Slamon, D.

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

CLINICAL CANCER RESEARCH. 2022; 28(6): 1107-1116 Nº de citas: 9 [doi:10.1158/1078-0432.CCR-21-2652]

Alsar, JS; de la Tabla, AGO; Moran, LO; Martin, AJM.

Treatment modalities in cancer-associated venous thromboembolism (VTE)

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2022; 35(1): Nº de citas: 2 [doi:10.1016/j.beha.2022.101354]

Lopez-Tarruella, S; Echavarria, I; Jerez, Y; Herrero, B; Gamez, S; Martin, M.

How we treat HR-positive, HER2-negative early breast cancer

Future Oncology. 2022; 18(8): 1003-1022 Nº de citas: 11 [doi:10.2217/fon-2021-0668]

Garcia-Alfonso, P; Saiz-Rodriguez, M; Mondejar, R; Salazar, J; Paez, D; Borobia, AM; Safont, MJ; Garcia-Garcia, I; Colomer, R; Garcia-Gonzalez, X; Herrero, MJ; Lopez-Fernandez, LA; Abad-Santos, F.

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

CLINICAL & TRANSLATIONAL ONCOLOGY. 2022; 24(3): 483-494 Nº de citas: 31 [doi:10.1007/s12094-021-02708-4]

Ledermann, JA; Zurawski, B; Raspagliesi, F; De Giorgi, U; Arija, JA; Marin, MR; Lisyanskaya, A; Poka, RL; Markowska, J; Cebotaru, C; Herraez, AC; Colombo, N; Kutarska, E; Hall, M; Jacobs, A; Ahrens-Fath, I; Baumeister, H; Zurlo, A; Sehouli, J.

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

Esmo Open. 2022; 7(1): Nº de citas: 8 [doi:10.1016/j.esmoop.2021.100311]

Calvo, A; Gonzalez-Hidalgo, M; Terleira, A; Fernandez, N; Portoles, A.

Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers

Journal of Clinical Medicine. 2022; 11(4): Nº de citas: 1 [doi:10.3390/jcm11041141]